Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · third_quarter · 3A
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Source: Senate LDA
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Cancer Drug Coverage Parity Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Cancer Drug Coverage Parity Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
To amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
To amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Generating Antibiotic Incentives Now Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Generating Antibiotic Incentives Now Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753/HR 6517)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753/HR 6517)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Prostate Research, Outreach, Screening, Testing, Access, and Treatment Effectiveness Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Prostate Research, Outreach, Screening, Testing, Access, and Treatment Effectiveness Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Superfund Polluter Pays Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Superfund Polluter Pays Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Superfund Polluter Pays Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Superfund Polluter Pays Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Superfund Polluter Pays Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Superfund Polluter Pays Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · first_quarter · Q1
Issues related to the pharmaceutical sales fee (no specific bills) Issues related to the renewal of the R&D tax credit (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (no specific bills) Issues related to the supply of medical isotopes (the American Medical Isotopes Production Act (S.99)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · fourth_quarter · Q4
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753/HR 6517)).
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · third_quarter · Q3
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · second_quarter · 2A
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · second_quarter · Q2
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE